Arctiin是Arctium lappa L. (A. lappa) 的一种生物活性代谢物，是一种口服有效的NF-κB抑制剂。
Cas No.:20362-31-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Arctiin, a bioactive metabolite from Arctium lappa L. (A. lappa), is an orally active inhibitor of NF-κB [1]. Arctiin can inhibit the PI3K/AKT and JAK/STAT signaling pathways, reduce the expression of S100A4 protein, and hinder cell migration[2]. Arctiin has been widely used in various animal models to inhibit inflammation and combat viral infections[3].
In vitro, Arctiin treatment for 48 hours significantly inhibited the growth of SW480 cells with an IC50 value of 220.7µM [4]. Treatment with 2mg/ml Arctiin for 48 hours induced cell cycle arrest at G0/G1 phase and inhibited the proliferation of human retinal capillary endothelial cells (HRCECs) induced by high concentration (4.5mg/ml) glucose[5]. Treatment of U266 cells with 10µM Arctiin for 36 hours significantly hindered cell proliferation, arrested the cell cycle at G2/M phase, and induced cell apoptosis[6].
In vivo, Arctiin (80mg/kg) was administered orally once daily for 3 weeks to attenuate myocardial hypertrophy and inhibit myocardial fibrosis and collagen deposition in mice undergoing aortic banding[7]. Arctiin (25mg/kg) was intraperitoneally injected once a day for 16 consecutive days, which effectively alleviated 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis (AD)-like skin lesions in mice, reduced skin thickness, mast cell infiltration in skin tissue, and serum total IgE level[8].
References:
[1] Yang M, Peng G, Abudouwanli A, et al. Immunopharmacological potential of Arctium lappa L. in immune-mediated skin diseases: A critical review of experimental and clinical evidence[J]. Frontiers in Pharmacology, 2025, 16: 1660352.
[2] Chowdhury R, Bhuia M S, Wilairatana P, et al. An insight into the anticancer potentials of lignan arctiin: A comprehensive review of molecular mechanisms[J]. Heliyon, 2024, 10(12).
[3] Gao Q, Yang M, Zuo Z. Overview of the anti-inflammatory effects, pharmacokinetic properties and clinical efficacies of arctigenin and arctiin from Arctium lappa L[J]. Acta Pharmacologica Sinica, 2018, 39(5): 787-801.
[4] Yoo J H, Lee H J, Kang K, et al. Lignans inhibit cell growth via regulation of Wnt/β-catenin signaling[J]. Food and Chemical Toxicology, 2010, 48(8-9): 2247-2252.
[5] Zhou M, Li G, Zhu L, et al. Arctiin attenuates high glucose‐induced human retinal capillary endothelial cell proliferation by regulating ROCK1/PTEN/PI3K/Akt/VEGF pathway in vitro[J]. Journal of Cellular and Molecular Medicine, 2020, 24(10): 5695-5706.
[6] Lee J H, Kim C, Lee J, et al. Arctiin is a pharmacological inhibitor of STAT3 phosphorylation at tyrosine 705 residue and potentiates bortezomib-induced apoptotic and anti-angiogenic effects in human multiple myeloma cells[J]. Phytomedicine, 2019, 55: 282-292.
[7] Li J, Yuan Y P, Xu S C, et al. Arctiin protects against cardiac hypertrophy through inhibiting MAPKs and AKT signaling pathways[J]. Journal of Pharmacological Sciences, 2017, 135(3): 97-104.
[8] Li J, Du X, Mu Z, et al. Arctiin Alleviates Atopic Dermatitis Against Inflammation and Pyroptosis Through Suppressing TLR4/MyD88/NF-κB and NLRP3/Caspase-1/GSDMD Signaling Pathways[J]. Journal of Inflammation Research, 2024: 8009-8026.
Arctiin是Arctium lappa L. (A. lappa) 的一种生物活性代谢物，是一种口服有效的NF-κB抑制剂[1]。Arctiin能够抑制PI3K/AKT和JAK/STAT信号通路，降低S100A4蛋白的表达，并阻碍细胞迁移[2]。Arctiin已被广泛用于多种动物模型以抑制炎症和抗病毒感染[3]。
在体外，Arctiin处理48小时显著抑制了SW480细胞的生长，IC50值为220.7µM[4]。使用2mg/ml的Arctiin处理48小时，可诱导细胞周期阻滞在G0/G1期，并抑制高浓度（4.5mg/ml）葡萄糖诱导的人视网膜毛细血管内皮细胞（HRCECs）增殖[5]。用10µM的Arctiin处理U266细胞36小时，显著阻碍细胞增殖，将细胞周期阻滞在G2/M期，并诱导细胞凋亡[6]。
在体内，每日口服给予Arctiin（80mg/kg）一次，持续3周，可减轻主动脉弓缩窄小鼠的心肌肥大，并抑制心肌纤维化和胶原沉积[7]。连续16天每日腹腔注射Arctiin（25mg/kg），有效缓解了2,4-dinitrochlorobenzene（DNCB）诱导的小鼠特应性皮炎（AD）样皮肤损伤，减轻了皮肤厚度、皮肤组织中的肥大细胞浸润以及血清总IgE水平[8]。
| Cell experiment [1]: | |
Cell lines | SW480 cells |
Preparation Method | SW480 cells were cultured in RPMI-1640 medium supplemented with 200mM HEPES, 10% (w/v) heat-inactivated fetal bovine serum (FBS), and 1% (w/v) penicillin-streptomycin. Cells were cultured in T-75 flasks and 100mm Petri dishes at 37°C in a humidified environment with 5% CO2 and sub-cultured twice a week with 0.25% trypsin containing 1mM EDTA. SW480 cells were seeded in 96-well flat bottom plates at a density of 6×103 cells/well. After incubation at 37°C for 24 hours, the medium was replaced, and Arctiin diluted to different concentrations (12.5, 100, 200, 300, 400µM) was added. Control cells were treated with DMSO at a final concentration of 1%. Cell proliferation was measured 48 hours later. |
Reaction Conditions | 12.5, 100, 200, 300, 400µM; 48h |
Applications | Arctiin treatment reduced cell viability of SW480 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male C57/B6 mice |
Preparation Method | Eighty adult male C57/B6 mice (8-10 weeks old; 23.5-27.5g) were housed in a standard sterile environment, and 40 of the mice underwent aortic banding (AB) one week after acclimatization to the laboratory environment. Subjects were randomly divided into four groups: sham+vehicle group (n=20), sham+Arctiin group (n=20), AB+vehicle group (n=20), and AB+Arctiin group (n=20). One week after AB, Arctiin was administered by regular daily gavage at a dose of 80mg/kg for 3 weeks. The control group was given the same volume of vehicle. All mice were anesthetized with 1.5% isoflurane and sacrificed by cervical dislocation. Heart samples were dissected and collected for analysis. |
Dosage form | 80mg/kg/day for 3 weeks; p.o. |
Applications | Arctiin treatment attenuated cardiac hypertrophy induced by AB, and suppressed cardiac fibrosis and accumulation of collagen in mice. |
References: | |
| Cas No. | 20362-31-6 | SDF | |
| 别名 | 牛蒡子苷; Arctii; NSC 315527; Arctigenin-4-glucoside | ||
| 化学名 | (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl]oxolan-2-one | ||
| Canonical SMILES | COC1=C(C=C(C=C1)CC2COC(=O)C2CC3=CC(=C(C=C3)OC4C(C(C(C(O4)CO)O)O)O)OC)OC | ||
| 分子式 | C27H34O11 | 分子量 | 534.55 |
| 溶解度 | ≥ 23.3mg/mL in DMSO | 储存条件 | Store at -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8707 mL | 9.3537 mL | 18.7073 mL |
| 5 mM | 374.1 μL | 1.8707 mL | 3.7415 mL |
| 10 mM | 187.1 μL | 935.4 μL | 1.8707 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet